- Markets
- Healthcare
- ZIMLAB
ZIMLAB
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
ZIM Laboratories Gets Marketing Authorization For Dimethyl Fumarate Capsules In Portugal
March 19 (Reuters) - Zim Laboratories Ltd ZIML.NS:
ZIM LABORATORIES - GETS MARKETING AUTHORIZATION FOR DIMETHYL FUMARATE CAPSULES IN PORTUGAL
ZIM LABORATORIES- AUTHORISATION WILL FACILITATE FASTER APPROVALS IN OTHER EU NATIONS AS WELL AS UK
Source text: ID:nNSE9dZvtp
Further company coverage: ZIML.NS
(([email protected];))
March 19 (Reuters) - Zim Laboratories Ltd ZIML.NS:
ZIM LABORATORIES - GETS MARKETING AUTHORIZATION FOR DIMETHYL FUMARATE CAPSULES IN PORTUGAL
ZIM LABORATORIES- AUTHORISATION WILL FACILITATE FASTER APPROVALS IN OTHER EU NATIONS AS WELL AS UK
Source text: ID:nNSE9dZvtp
Further company coverage: ZIML.NS
(([email protected];))
Zim Laboratories Gets Marketing Authorization For Buprenorphine Sublingual Film In Europe
Jan 10 (Reuters) - Zim Laboratories Ltd ZIML.NS:
ZIM LABORATORIES- GRANT OF MARKETING AUTHORIZATION FOR BUPRENORPHINE SUBLINGUAL FILM IN EUROPE
Source text: ID:nNSE4RLMTX
Further company coverage: ZIML.NS
(([email protected];;))
Jan 10 (Reuters) - Zim Laboratories Ltd ZIML.NS:
ZIM LABORATORIES- GRANT OF MARKETING AUTHORIZATION FOR BUPRENORPHINE SUBLINGUAL FILM IN EUROPE
Source text: ID:nNSE4RLMTX
Further company coverage: ZIML.NS
(([email protected];;))
Zim Laboratories Invests Upto Euro 1,50,000 In Shares Of Sia Zim Laboratories
Sept 30 (Reuters) - Zim Laboratories Ltd ZIML.NS:
INVESTMENT OF UPTO EURO 1,50,000 IN EQUITY SHARES OF SIA ZIM LABORATORIES
Source text for Eikon: ID:nNSE1KG1zS
Further company coverage: ZIML.NS
(([email protected];;))
Sept 30 (Reuters) - Zim Laboratories Ltd ZIML.NS:
INVESTMENT OF UPTO EURO 1,50,000 IN EQUITY SHARES OF SIA ZIM LABORATORIES
Source text for Eikon: ID:nNSE1KG1zS
Further company coverage: ZIML.NS
(([email protected];;))
Zim Laboratories Says Upto 3 Million Shares Of Co Held By A Public Shareholder Proposed To Be Sold
June 12 (Reuters) - Zim Laboratories Ltd ZIML.NS:
ZIM LABORATORIES LTD - UP TO 3 MILLION SHARES OF CO HELD BY A PUBLIC SHAREHOLDER PROPOSED TO BE SOLD THROUGH ONE OR MORE PERMITTED MEANS
Source text for Eikon: ID:nBSE95qMS8
Further company coverage: ZIML.NS
(([email protected];))
June 12 (Reuters) - Zim Laboratories Ltd ZIML.NS:
ZIM LABORATORIES LTD - UP TO 3 MILLION SHARES OF CO HELD BY A PUBLIC SHAREHOLDER PROPOSED TO BE SOLD THROUGH ONE OR MORE PERMITTED MEANS
Source text for Eikon: ID:nBSE95qMS8
Further company coverage: ZIML.NS
(([email protected];))
India's Zim Laboratories March-Quarter Consol PAT Rises
May 19 (Reuters) - Zim Laboratories Ltd ZIML.NS:
MARCH-QUARTER CONSOL PAT 72.4 MILLION RUPEES VERSUS 70.3 MILLION RUPEES
MARCH-QUARTER CONSOL TOTAL INCOME 1.06 BILLION RUPEES VERSUS 1.07 BILLION RUPEES
Further company coverage: ZIML.NS
(([email protected];))
May 19 (Reuters) - Zim Laboratories Ltd ZIML.NS:
MARCH-QUARTER CONSOL PAT 72.4 MILLION RUPEES VERSUS 70.3 MILLION RUPEES
MARCH-QUARTER CONSOL TOTAL INCOME 1.06 BILLION RUPEES VERSUS 1.07 BILLION RUPEES
Further company coverage: ZIML.NS
(([email protected];))
Zim Laboratories Says Not Received Any Show-Cause Notice Or Any Notice To Stop Manufacturing From Any Drug Authority
April 21 (Reuters) - Zim Laboratories Ltd ZIML.NS:
NOT RECEIVED ANY SHOW-CAUSE NOTICE OR ANY NOTICE TO STOP MANUFACTURING FROM ANY DRUG AUTHORITY
Source text for Eikon: ID:nNSE97BDRC
Further company coverage: ZIML.NS
(([email protected];))
April 21 (Reuters) - Zim Laboratories Ltd ZIML.NS:
NOT RECEIVED ANY SHOW-CAUSE NOTICE OR ANY NOTICE TO STOP MANUFACTURING FROM ANY DRUG AUTHORITY
Source text for Eikon: ID:nNSE97BDRC
Further company coverage: ZIML.NS
(([email protected];))
Events:
Bonus
Dividend
Bonus
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Zim Laboratories do?
Zim Laboratories Ltd is a leading healthcare solution provider specializing in New Drug Delivery Systems. They have developed innovative technologies and products in areas such as Pellets, Multiplets, Resinates, Herbals, and Diagnostics.
Who are the competitors of Zim Laboratories?
Zim Laboratories major competitors are Venus Remedies, Jenburkt Pharma, Brooks Laboratories, Lyka Labs, Medico Remedies, Albert David, Ind-Swift Lab.. Market Cap of Zim Laboratories is ₹447 Crs. While the median market cap of its peers are ₹489 Crs.
Is Zim Laboratories financially stable compared to its competitors?
Zim Laboratories seems to be less financially stable compared to its competitors. Altman Z score of Zim Laboratories is 3.04 and is ranked 8 out of its 8 competitors.
Does Zim Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Zim Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Zim Laboratories allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Zim Laboratories balance sheet?
Balance sheet of Zim Laboratories is strong. But short term working capital might become an issue for this company.
Is the profitablity of Zim Laboratories improving?
No, profit is decreasing. The profit of Zim Laboratories is ₹15.37 Crs for TTM, ₹17.25 Crs for Mar 2024 and ₹24.43 Crs for Mar 2023.
Is the debt of Zim Laboratories increasing or decreasing?
Yes, The debt of Zim Laboratories is increasing. Latest debt of Zim Laboratories is ₹91.54 Crs as of Sep-24. This is greater than Mar-24 when it was ₹85.4 Crs.
Is Zim Laboratories stock expensive?
Yes, Zim Laboratories is expensive. Latest PE of Zim Laboratories is 29.12, while 3 year average PE is 27.39. Also latest EV/EBITDA of Zim Laboratories is 12.03 while 3yr average is 10.52.
Has the share price of Zim Laboratories grown faster than its competition?
Zim Laboratories has given lower returns compared to its competitors. Zim Laboratories has grown at ~13.82% over the last 6yrs while peers have grown at a median rate of 20.44%
Is the promoter bullish about Zim Laboratories?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Zim Laboratories is 33.26% and last quarter promoter holding is 33.26%.
Are mutual funds buying/selling Zim Laboratories?
There is Insufficient data to gauge this.